Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EXPAND IT

Financiado

EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapy

Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized the treatment of advanced-stage cancers. One of the major limitations of ICB is that durable responses are observed only in a subset of patients and in... ver más

31/12/2027

VLAAMS INSTITUUT...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-09-29

ERC-2021-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RARITY RAtional design of canceR ImmunoTherapY one size does not f... 1M€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

CANCER-DC Dissecting Regulatory Networks That Mediate Dendritic Cell S... 2M€ Cerrado

IOO - Improving IO IOO: a novel assay to predict patient response to immune che... 4M€ Cerrado

STIC-GBM Spatio-temporal dynamics of immune circuitry in glioblastoma... 174K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2022-09-29
Fecha Fin: 2027-12-31

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized the treatment of advanced-stage cancers. One of the major limitations of ICB is that durable responses are observed only in a subset of patients and in some specific cancer types. We recently analyzed tumor biopsies from breast cancer patients collected during ICB and indeed observed only in a subset of patients that tumor-infiltrating T-cells undergo rapid expansion when exposed to ICB. We characterized the gene expression programs underlying this expansion at single-cell level and realized that - although these expanding T-cells are the main executors of therapeutic response to ICB - several key questions regarding their function remain unanswered. First, we lack accurate knowledge about where in the heterogeneous tumor microenvironment (TME) and in which metabolic niches T-cell expansion occurs. Secondly, based on their TCR sequence we cannot predict upfront which T-cells will expand (or rather act as bystander T-cells), nor can we say to which tumor antigens these expanding T-cells are directed. Thirdly, it is not known which molecular events underlie the generation of the tumor antigens regulating T-cell expansion. Fourthly, we also observed an expansion of the B-cell repertoire and were left with similar questions as for expanding T-cells. For instance, where are expanding B-cells located, how do they interact with expanding T-cells, and do they perhaps even recognize the same tumor antigens. In EXPAND IT, we will use several innovative (single-cell) technologies to provide answers to these questions. These insights will much better characterize the mechanisms driving response to ICB, but will also provide important answers on how to sensitize patients not responding to ICB. Our findings could also contribute to the discovery of high-avidity anti-tumor TCRs that can be used in novel TCR-based cellular therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores